

Original Article

Cite this article: Buckman JEJ *et al* (2021). Role of age, gender and marital status in prognosis for adults with depression: An individual patient data meta-analysis. *Epidemiology and Psychiatric Sciences* **30**, e42, 1–13. <https://doi.org/10.1017/S2045796021000342>

Received: 20 January 2021

Revised: 4 May 2021

Accepted: 9 May 2021

Keywords:

Depression; individual patient data meta-analysis; prognosis; systematic review; treatment outcomes

Author for correspondence:

Joshua E. J. Buckman,

E-mail: Joshua.buckman@ucl.ac.uk

Role of age, gender and marital status in prognosis for adults with depression: An individual patient data meta-analysis

J. E. J. Buckman^{1,2} , R. Saunders¹, J. Stott¹, L.-L. Arundell¹ , C. O'Driscoll¹, M. R. Davies³ , T. C. Eley³, S. D. Hollon⁴, T. Kendrick⁵, G. Ambler⁶, Z. D. Cohen⁷, E. Watkins⁸, S. Gilbody⁹, N. Wiles¹⁰, D. Kessler¹¹, D. Richards^{12,13}, S. Brabyn⁹, E. Littlewood⁹, R. J. DeRubeis¹⁴, G. Lewis¹⁵  and S. Pilling^{1,16}

¹Research Department of Clinical, Educational & Health Psychology, Centre for Outcomes Research and Effectiveness (CORE), University College London, 1-19 Torrington Place, London WC1E 7HB, UK; ²Cope – Camden & Islington NHS Foundation Trust, St Pancras Hospital, London NW1 0PE, UK; ³Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London SE5 8AF, UK; ⁴Department of Psychology, Vanderbilt University, Nashville, TN 37240, USA; ⁵Faculty of Medicine, Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton SO16 5ST, UK; ⁶Statistical Science, University College London, London WC1E 7HB, UK; ⁷Department of Psychiatry, University of California, Los Angeles, Los Angeles, CA, 90095, USA; ⁸Department of Psychology, University of Exeter, Exeter EX4 4QG, UK; ⁹Department of Health Sciences, University of York, York YO10 5DD, UK; ¹⁰Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Oakfield House, Bristol BS8 2BN, UK; ¹¹Centre for Academic Primary Care, Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, Bristol, UK; ¹²Institute of Health Research, University of Exeter College of Medicine and Health, Exeter EX1 2LU, UK; ¹³Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Inndalsveien 28, 5063 Bergen, Norway; ¹⁴Department of Psychology, School of Arts and Sciences, 425 S. University Avenue, Philadelphia PA, 19104-60185, USA; ¹⁵Division of Psychiatry, University College London, London W1T 7NF, UK and ¹⁶Camden & Islington NHS Foundation Trust, 4 St Pancras Way, London NW1 0PE, UK

Abstract

Aims. To determine whether age, gender and marital status are associated with prognosis for adults with depression who sought treatment in primary care.

Methods. Medline, Embase, PsycINFO and Cochrane Central were searched from inception to 1st December 2020 for randomised controlled trials (RCTs) of adults seeking treatment for depression from their general practitioners, that used the Revised Clinical Interview Schedule so that there was uniformity in the measurement of clinical prognostic factors, and that reported on age, gender and marital status. Individual participant data were gathered from all nine eligible RCTs ($N = 4864$). Two-stage random-effects meta-analyses were conducted to ascertain the independent association between: (i) age, (ii) gender and (iii) marital status, and depressive symptoms at 3–4, 6–8, <Vinod: Please carry out the deletion of serial commas throughout the article> and 9–12 months post-baseline and remission at 3–4 months. Risk of bias was evaluated using QUIPS and quality was assessed using GRADE. PROSPERO registration: CRD42019129512. Pre-registered protocol <https://osf.io/e5zup/>.

Results. There was no evidence of an association between age and prognosis before or after adjusting for depressive ‘disorder characteristics’ that are associated with prognosis (symptom severity, durations of depression and anxiety, comorbid panic disorder and a history of antidepressant treatment). Difference in mean depressive symptom score at 3–4 months post-baseline per 5-year increase in age = 0 (95% CI: –0.02 to 0.02). There was no evidence for a difference in prognoses for men and women at 3–4 months or 9–12 months post-baseline, but men had worse prognoses at 6–8 months (percentage difference in depressive symptoms for men compared to women: 15.08% (95% CI: 4.82 to 26.35)). However, this was largely driven by a single study that contributed data at 6–8 months and not the other time points. Further, there was little evidence for an association after adjusting for depressive ‘disorder characteristics’ and employment status (12.23% (–1.69 to 28.12)). Participants that were either single (percentage difference in depressive symptoms for single participants: 9.25% (95% CI: 2.78 to 16.13)) or no longer married (8.02% (95% CI: 1.31 to 15.18)) had worse prognoses than those that were married, even after adjusting for depressive ‘disorder characteristics’ and all available confounders.

Conclusion. Clinicians and researchers will continue to routinely record age and gender, but despite their importance for incidence and prevalence of depression, they appear to offer little information regarding prognosis. Patients that are single or no longer married may be expected to have slightly worse prognoses than those that are married. Ensuring this is recorded routinely alongside depressive ‘disorder characteristics’ in clinic may be important.

© The Author(s), 2021. Published by Cambridge University Press. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.

Introduction

Patients and clinicians can benefit from prognostic information (Hayden *et al.*, 2013). Such knowledge can inform routine clinical assessments and triages of patients seeking treatment for depression and might guide the collaborative treatment decision-making process. This information does not help determine which treatment may be most likely to benefit any individual patient, but instead, informs considerations of the intensity, dose or duration of treatment, the regularity of progress reviews and referrals to specialist treatment centres (Buckman *et al.*, 2021). This would be particularly true if the differences in prognoses for patients with one compared to another pre-treatment characteristic were of a clinically important magnitude (Button *et al.*, 2015). Prognostic information is often wanted by patients and clinicians (Trusheim *et al.*, 2007). However, prognostication for adults with depression is challenging as most prior studies have considered prognosis following one particular type of treatment, or in samples where either no treatment was given or details regarding any treatment(s) are unknown (Buckman *et al.*, 2020; Buckman *et al.*, 2021). As there is an approximate equivalence (on average) in the effectiveness of the most common types of treatment for depression (Menchetti *et al.*, 2010; Cuijpers *et al.*, 2013; Weitz *et al.*, 2017; Cipriani *et al.*, 2018), and a number of prognostic factors have been found to be associated with outcomes from one type of treatment but not others (Dodd *et al.*, 2014; Chekroud *et al.*, 2016; Nakabayashi *et al.*, 2018; Buckman *et al.*, 2021), there is a need to study prognosis regardless of the type of treatment received. Doing so would identify factors that are associated with prognosis in general, which would be informative for clinicians assessing and treating patients with depression in a breadth of settings. We call this prognosis independent of treatment. This form of prognosis has been largely overlooked in studies of depression (Buckman *et al.*, 2020; Buckman *et al.*, 2021). We recently found that a number of clinical factors were associated with prognosis independent of treatment, and that each contributed to explaining prognosis over and above depressive symptom severity (Buckman *et al.*, 2021). We termed these depressive ‘disorder characteristics’. These were: the durations of depression and anxiety problems, comorbid panic disorder and a history of antidepressant medication, each should be routinely assessed in clinic alongside depressive symptom severity. Whether other factors are similarly associated with prognosis and add incremental value to prognostic assessments is uncertain.

For decades it has been shown that age, gender and marital status are associated with the prevalence of depression (Ensel, 1982; Kessler and Essex, 1982; Bebbington, 1987; Faravelli *et al.*, 2013). Previous reviews of the relationship between these factors and post-treatment prognosis have found inconsistent results. For example, three reviews reported that older age was associated with worse prognosis (Cuijpers *et al.*, 2018; Nakabayashi *et al.*, 2018; Sockol, 2018); two found no such association (Johnsen and Friberg, 2015; Karyotaki *et al.*, 2017); and one found that prognosis improved with increasing age (Noma *et al.*, 2019). Similarly, four reviews reported that women had poorer prognoses than men (Carter *et al.*, 2012; Dodd *et al.*, 2014; Johnsen and Friberg, 2015; Noma *et al.*, 2019), while four reported no such association (Karyotaki *et al.*, 2017; Cuijpers *et al.*, 2018; Nakabayashi *et al.*, 2018; Schoemaker *et al.*, 2018). Two reviews reported better prognoses for married individuals (Carter *et al.*, 2012; Sockol, 2018) while a third found no evidence for this association (Karyotaki *et al.*, 2017).

There are clear limitations, most of these past studies are not directly comparable as the reviews examined specific treatments only (e.g., duloxetine or Interpersonal Psychotherapy), and the sample settings were unclear or unstated. None of the past reviews presented results adjusted for the effects of multiple known clinical prognostic factors (Buckman *et al.*, 2021). To do so accurately, for factors that differ at the individual patient level requires individual patient data (IPD) (Rothwell, 2005; Fisher, 2015) and only four of the past reviews had IPD. Two were not systematic reviews and made no adjustment for any clinical factors (Nakabayashi, Hara and Minami, 2018; Noma *et al.*, 2019). Two others adjusted for baseline depressive symptom severity (Dodd *et al.*, 2014; Karyotaki *et al.*, 2017). The first (Dodd *et al.*, 2014) made no adjustments for between-study effects and no assessments of either attrition or heterogeneity, limiting the robustness and interpretability of the findings. The second was an investigation of potential moderators of treatment effects and found high levels of heterogeneity that could not be explained (Karyotaki *et al.*, 2017). Clarity on the association of these factors with prognosis is needed, particularly for patients initially seeking treatment in primary care as large proportions of adults are either initially screened and assessed or are wholly treated for depression in primary care settings (McManus *et al.*, 2016; Olfson *et al.*, 2016; Thornicroft *et al.*, 2017).

Given these contrasting results, we aimed to determine whether age, gender and marital status are associated with prognosis for adults with depression who sought treatment in primary care. We investigated these associations after accounting for the effect of known clinical prognostic factors, the depressive ‘disorder characteristics’ we identified previously (Buckman *et al.*, 2021), and regardless of the type of treatment. In so doing, we aimed to determine whether these factors add incrementally to knowledge of prognosis at the point patients initially seek treatment.

Methods

This systematic review with IPD meta-analysis is reported in accordance with the PRISMA-IPD statement (Stewart *et al.*, 2015) (checklist in online Supplementary materials).

Identification and selection of studies

A protocol for this study was pre-registered (<https://osf.io/e5zup/>). A general protocol for forming the Depression in General Practice (Dep-GP) IPD dataset and the plan for analysing those data (Buckman *et al.*, 2020) and pre-registered methods for identifying studies are also available (PROSPERO: CRD42019129512 (01/04/2019)), and were reported in accordance with the PRISMA-P statement (Shamseer *et al.*, 2015). Searches have been reported in accordance with PRISMA-S (Rethlefsen *et al.*, 2021), with a brief description below and more details provided in online Supplementary Materials.

Searches were conducted on Medline, Embase, International Pharmaceutical Abstracts, PsycINFO and Cochrane Central (searched from inception to 1st December 2020), we also hand-searched reference lists, and contacted experts for unpublished or missed studies. Search terms included variations of phrases such as ‘depression’ or ‘major depression’, ‘RCT’ or ‘Randomised Controlled Trial’ and ‘CIS-R’ or ‘Clinical Interview Schedule’. See online Supplementary Table 1 for a full list and results of the searches.

A single reviewer (JB) screened titles and abstracts of potentially eligible studies, these were then read in full and judged against inclusion/exclusion criteria by two reviewers (JB and GL) with consultation with a third (SP) to resolve any uncertainties by consensus.

Inclusion and exclusion criteria

Studies were included if they were RCTs of adults (aged 16 or over) with unipolar depression, depressive symptoms significant enough to seek treatment, or a Revised Clinical Interview Schedule (CIS-R) (Lewis *et al.*, 1992) score of ≥ 12 (the cut-off for common mental disorder); recruited from primary care; had at least one active treatment arm; used the CIS-R at baseline, and assessed marital status, age and gender at baseline.

Studies were excluded if they: included patients with depression secondary to a diagnosis of personality disorder, psychotic conditions or neurological conditions; were studies of adults with bi-polar or psychotic depressions; were studies of children or adolescents; were feasibility studies; were studies of just one gender, one particular age group or one marital status group only.

Data extraction

The included studies are detailed in Table 1. Data were extracted for each study participant on all measures included in Table 2 and additional socio-demographics listed in Table 3 by the chief investigators or data managers of each study. Data were independently cleaned by two independent reviewers (JB and RS). Issues were resolved by consensus between four reviewers (JB, RS, GL and SP).

Data integrity checks

Integrity of all baseline and endpoint data for each study was checked with the study team and against publications from each study. We removed two participants from IPCRESS and one from PANDA due to them missing data on over 75% of baseline variables. There were also data available on 36 more participants in ITAS than reported in the publication about that study.

Ethical considerations

All studies were granted NHS Research ethical approvals and all participants gave informed consent, see online Supplementary Table 2. No additional ethical approval was required for this study: HRA reference 712/86/32/81.

Measures

See Table 2 for details.

Data analysis plan

The pre-registered analysis plan (<https://osf.io/e5zup/>) is outlined below. It builds on the plan outlined in our general protocol (Buckman *et al.*, 2020).

Primary outcomes

Depressive symptoms at 3–4 months post-baseline were captured in two ways. (1) *z*-score (standardised mean) of the scores on the depressive symptom measures (BDI-II and PHQ-9) used at 3–4 months post-baseline within each study (see Table 1). The score at 3–4 months was divided by the standard deviation for that measure calculated at 3–4 months. (2) The logarithm of depression scale scores irrespective of the measure used.

Exponentiation of the regression coefficient provides an estimate of the percentage difference in symptoms.

It was expected that these methods would give similar results but the log outcome might have greater utility as percentage differences are more easily understood and do not require division by standard deviation estimates.

Secondary outcomes

- 1) Remission on the primary depression measure in each study at 3–4 months post-baseline (a score of < 10 on the BDI-II or PHQ-9, whichever was the primary measure collected at that time point in each study).
- 2) Depressive symptoms at 6–8 months post-baseline, as above but also including the GHQ-12, captured with (i) the *z*-score calculated using the mean and standard deviation for the scores at 3–4 months and (ii) the logarithm of scores at 6–8 months.
- 3) Depressive symptoms at 9–12 months post-baseline, as above, captured with (i) the *z*-score calculated using the mean and standard deviation for the scores at 3–4 months and (ii) the logarithm of scores at 9–12 months.

Prognostic indicators under consideration

- 1) Age was considered both as a continuous variable per 5-year increase, and in age groups: (i) 16–29 (ii) 30–39; (iii) 40–49; (iv) 50–59; (v) ≥ 60 years old.
- 2) Gender was taken from a question asking participants for their self-reported gender at baseline, in all included studies response options were binary. This was commonplace in studies at the time, it does not capture the appropriate range of gender identities, neither does it capture differences between gender and sex assigned at birth.
- 3) Marital status was initially recorded in five categories: (1) married or cohabiting (living with partner); (2) single (never married), (3) separated, (4) divorced, (5) widowed. However, some of the studies had very few participants that were divorced ($n = 0$ in ITAS) and widowed ($n = 4$ in GENPOD, $n = 1$ in IPCRESS and $n = 6$ in TREAD). Therefore, marital status was recoded into three categories to meet power requirements by combining categories 3–5 above in a new category ‘no longer married’.

Confounders and covariates

Data on some potential confounders were available in all studies whereas data on others were not (i.e., systematically missing). Following our protocol, we adjusted for the following in separate models of each outcome:

- 1) Depressive ‘disorder characteristics’: depressive symptom severity, the duration of the current depressive episode, mean duration of anxiety problems, comorbid panic disorder and a history of antidepressant treatment.
- 2) Age, gender and marital status (excluding whichever of these was already included in the model as the potential prognostic factor).
- 3) Employment status.

In sensitivity analyses we then added each of the systematically missing variables one at a time:

- 1) Housing status (available in eight studies).
- 2) Long-term physical health condition status (yes/no; available in eight studies).

Table 1. Description of included studies

Study	N	Inclusion criteria	Age	Gender	Marital status	To depressive severity	Remission	Interventions	Outcome measure
			Mean (s.d.)	% Female	% married, single, no longer married	mean (s.d.)	% at 3–4 months		primary (additional)
CADET (Richards <i>et al.</i> , 2013)	527	Adults ≥ 18 , ICD-10 Depressive Episode	44.4(13.2)	72%	41.4% married; 30.2% single; 28.5% no longer married	PHQ-9 = 17.7(5.1)	41%	Collaborative Care vs TAU	PHQ-9
COBALT (Wiles <i>et al.</i> , 2013)	469	Adults 18–75 with treatment resistant depression, scoring ≥ 14 BDI-II	49.6(11.7)	72%	52.9% married; 19.0% single; 28.1% no longer married	BDI-II = 31.8(10.7)	34%	CBT + TAU vs TAU	BDI-II (PHQ-9)
GENPOD (Wiles <i>et al.</i> , 2012)	601	Adults 18–74 with depressive episode	38.8(12.4)	68%	52.6% married; 29.1% single; 18.3% no longer married	BDI-II = 33.7(9.7)	41%	Citalopram vs Reboxetine	BDI-II
IPCRESS (Kessler <i>et al.</i> , 2009)	295	Adults scoring ≥ 14 BDI-II and GP confirmed diagnosis of depression	34.9(11.6)	68%	36.6% married; 47.8% single; 15.6% no longer married	BDI-II = 33.2(8.8)	34%	iCBT + TAU vs TAU + waiting list for iCBT	BDI-II
ITAS (Thomas <i>et al.</i> , 2004)	798	Adults ≥ 16 , scored ≥ 12 on CIS-R	43.2(14.8)	68%	58.7% married; 22.4% single; 18.9% no longer married	GHQ = 7.7(3.2)	N/A; at 6-8 months 46%	Recommendation + TAU vs TAU	GHQ-12
MIR (Kessler <i>et al.</i> , 2018)	480	Adults ≥ 18 taking SSRIs or SNRIs at adequate dose for ≥ 6 weeks, and scored ≥ 14 on BDI-II	50.7(13.2)	69%	59.4% married; 19.6% single; 21.0% no longer married	BDI-II = 31.1(9.9)	30%	Mirtazapine vs Placebo	BDI-II (PHQ-9)
PANDA (Lewis <i>et al.</i> , 2019)	652	Adults presenting with low mood or depression to GP in last 2 years, free of ADM for 8 weeks up to baseline	39.7(15.0)	59%	39.1% married; 45.4% single; 15.5% no longer married	BDI-II = 23.9(10.3)	69%	Sertraline vs Placebo	PHQ-9 (BDI-II)
REEACT (Gilbody <i>et al.</i> , 2015)	685	Adults with PHQ-9 ≥ 10 presenting to GP with depression	39.9(12.7)	67%	50.9% married; 33.5% single; 15.6% no longer married	PHQ-9 = 16.7(4.3)	53%	Moodgym vs Beating the Blues vs TAU	PHQ-9
TREAD (Chalder <i>et al.</i> , 2012)	361	Adults 18-69 who met diagnostic criteria for MDD and scored ≥ 14 on BDI-II	39.8(12.6)	66%	46.3% married; 32.1% single; 21.6% no longer married	BDI-II = 32.1(9.2)	35%	Physical Activity + TAU vs TAU	BDI-II

Abbreviations: ADM, antidepressant medication; BDI-II, Beck Depression Inventory; EPDS, Edinburgh Postnatal Depression Scale; GHQ-12, General Health Questionnaire 12 item version; HADS-D, Hospital Anxiety and Depression Scale, depression subscale; iCBT (internet-based therapist delivered cognitive behavioural therapy); MDD, Major Depressive Disorder; T0 - Baseline; TAU, treatment as usual; TCA, tricyclic antidepressant.

Table 2. Measures used across the studies of the Dep-GP IPD dataset meeting inclusion criteria for the present study

Measure	Details	Scores and Cut-offs for Remission
The CIS-R (Lewis <i>et al.</i> , 1992)	Consists of 14 symptom subsections scored 0–4 covering core features of depression, depressive thoughts (scored 0–5), fatigue, concentration/forgetfulness, and sleep, generalised anxiety, worry, irritability, obsessions, compulsions, health anxiety, somatic concerns, phobic anxiety (split into agoraphobia, social phobia, and specific phobia), and panic. A final section measures general health, impairment and weight change.	The total score ranges from 0–57 with a cut-off of ≥ 12 used to indicate likely common mental disorder, primary and secondary diagnoses using ICD-10 criteria are given as are binary indicators of diagnosis for all the disorders assessed. The duration of each type of problem is also assessed for the present episode (or subsyndromal episode) up to the point of completing the CIS-R. Duration items are measured in five categories: (1) less than two weeks; (2) between two weeks and six months; (3) between six months and one year; (4) between one and two years; and (5) more than two years.
Beck Depression Inventory 2nd Edition (BDI-II) (Beck, Steer and Brown, 1996)	Consists of 21 items to assess depressive symptoms, each item is scored –3.	There is a maximum score obtainable of 63, and a cut-off of ≥ 10 is used indicate significant symptoms of depression, scores of < 10 are therefore used to indicate remission in those that were previously depressed/scored ≥ 10 .
Patient Health Questionnaire 9-item version (PHQ-9)(Kroenke, Spitzer and Williams, 2001)	This is a depression screening measure, with respondents asked to rate how often they have been bothered by each of the nine symptom items over the preceding two weeks. Each item is scored 0–3	There is a maximum score of 27 with a cut-off of ≥ 10 is used to indicate ‘caseness’ for depression, a score of 9 or below for those that were previously depressed is therefore considered to indicate remission
General Health Questionnaire (12-item version) (GHQ-12) (Goldberg, 1992)	Consists of 12 items related to present and recent health over the ‘few weeks’ prior to completion. Each item is related to depression or generalised anxiety, they are scored 0-0-1-1 for the four response options.	A cut-off of ≥ 2 is used to indicate the likely presence of common mental disorder, and so scores of < 2 for those formally scoring above this would be considered to indicate remission
Social Support Scale - adapted by authors of RCTs (Kessler <i>et al.</i> , 2009) included in this IPD by adding one item to the Health and Lifestyles Survey Social Support Measure (Cox <i>et al.</i> , 1987).	<i>An 8-item instrument (the first seven of which are from the Health and Lifestyles Survey) assessing the degree to which participants rated the social support of their friends and family in each of the following domains: (1) being accepted for who one is; (2) feeling cared about; (3) feeling loved; (4) feeling important to them; (5) being able to rely on them; (6) feeling well supported and encouraged by them; (7) being made to feel happy by them; and (8) feeling able to talk to them whenever one might like. Items are scored 1-3, with total scores ranging from 8 to 24; higher scores indicate higher levels of perceived social support. The authors of the Health and Lifestyles Survey suggested the maximum score for social support (which was 21 on that scale) indicated ‘no lack of social support’, scores between 18 and 20 indicated a ‘moderate lack of social support’, and scores of 17 or below indicated a ‘severe lack of social support’.</i>	N/A

CIS-R was used in all studies $n = 4864$. BDI-II was used in six studies (COBALT, GENPOD, IPCRESS, MIR, PANDA and TREAD), $n = 2858$; PHQ-9 was used in five studies (CADET, COBALT, MIR, PANDA and REEACT) $n = 2807$; GHQ was used in ITAS only $n = 796$; and the Social Support Scale was used in six studies (COBALT, GENPOD, IPCRESS, MIR, PANDA and TREAD) $n = 2858$.

- 3) Highest level of educational attainment (available in seven studies).
- 4) Financial wellbeing (available in six studies).
- 5) Social support (available in six studies).

In addition, all models were adjusted for treatment allocation by assigning each of the randomised groups across the studies a different category in a single categorical variable and including this variable in all models. This meant that associations between the prognostic factors and outcomes could be investigated having adjusted for the effects of the randomised treatments. It also meant that all models accounted for clustering effects at the study-level.

Data handling and data management

Details of the pre-processing stages and handling of missing data are given in the original protocol (Buckman *et al.*, 2020). Multiple imputation with chained equations was used with baseline and outcome variables to generate 50 imputed datasets for each study. Systematically missing variables were not imputed.

Primary analyses

Two-stage DerSimonian and Laird random effects meta-analyses were conducted for each prognostic factor (each fitted into separate models) for each outcome variable listed above, using the ‘admetan’ package (Fisher, 2015) in Stata 16 (StataCorp, 2019). Linear models were fitted for the z -score and log outcomes and

Table 3. Baseline characteristics of study sample using observed data only

Self-reported baseline characteristics	Factor	N(%) or N and Mean(s.d.)
Total sample size (N)		4864
Age in years		N: 4864, Mean(s.d.): 42.45(13.99)
Age 16–29 years old		1079(22.18%)
Age 30–39 years old		1043(21.44%)
Age 40–49 years old		1208(24.84%)
Age 50–59 years old		919(18.89%)
Age 60+ years old		615(12.64%)
Gender	Female	3279(67.41%)
	Male	1583(32.55%)
	Missing	2(0.04%)
Marital status	Married/cohabiting	2412(49.59%)
	Single	1477(30.37%)
	No longer married	975(20.05%)
Employment status	Employed	2713(55.81%)
	Not seeking employment	1199(24.67%)
	Unemployed	949(19.52%)
	Missing	3(0.06%)
Housing status	Home owner	2148(48.92%)
	Tenant	1677(38.19%)
	Other	566(12.89%)
	Missing	473(9.72%)
Financial wellbeing	Doing OK financially	1537(42.14%)
	Just about getting by	1171(32.11%)
	Struggling financially	939(25.75%)
	Missing	1217(25.02%)
Highest level of educational attainment	Degree or above	959(28.02%)
	A-level of diplomas	905(26.44%)
	GCSE	1016(29.68%)
	None or other	543(15.86%)
	Missing	1441(29.63%)
Long-term physical health condition	No	3244(73.81%)
	Yes	1151(26.19%)
	Missing	469(9.64%)
Social support scale score		N: 2858, Mean(s.d.): 20.25(3.85)
Past antidepressant use	No	1241(25.53%)
	Yes	3620(74.47%)
CIS-R durations	Depression	N: 4864, Mean(s.d.): 3.32(1.37)
	Average anxiety duration	N: 4813, Mean(s.d.): 2.05(0.98)

(Continued)

Table 3. (Continued.)

Self-reported baseline characteristics	Factor	N(%) or N and Mean(s.d.)
Comorbid panic disorder	No	4439(91.26%)
	Yes	425(8.74%)
Baseline BDI-II score		N: 2858, Mean(s.d.): 30.44(10.53)
Baseline PHQ-9 score		N: 2812, Mean(s.d.): 15.71(5.65)
Baseline GHQ-12 score		N: 795, Mean(s.d.): 7.69(3.22)
Attrition at 3–4 months	No	3411(70.13%)
	Yes	658(13.53%)
	Not applicable	795(16.34%)
BDI-II score 3–4 months		N:1918, Mean(s.d.): 16.07(11.99)
PHQ-9 score 3–4 months		N:2393, Mean(s.d.): 10.28(6.65)
Remission 3–4 months	No	1928(56.57%)
	Yes	1480(43.43%)
BDI-II score 6–8 months		N:1236, Mean(s.d.): 18.64(13.44)
PHQ-9 score 6–8 months		N:814, Mean(s.d.): 10.33(6.78)
GHQ-12 score 6–8 months		N:585, Mean(s.d.): 3.80(4.10)
Attrition at 6–8 months	No	1236(25.41%)
	Yes	369(7.59%)
	Not applicable	3259(67.00%)
BDI-II score 9–12 months		N:1028, Mean(s.d.): 16.78(12.87)
PHQ-9 score 9–12 months		N:1764, Mean(s.d.): 9.51(6.71)
Attrition at 9–12 months	No	2005(41.22%)
	Yes	516(10.61%)
	Not applicable	2343(48.17%)

logistic models were fitted for remission. The degree of heterogeneity was assessed using prediction intervals and its impact assessed using the I^2 statistic (Higgins *et al.*, 2003).

Risk of bias

Two reviewers (JB & RS) conducted independent risk of bias assessments using the Quality in Prognosis Studies (QUIPS) (Hayden *et al.*, 2013) and the quality of evidence for each prognostic indicator was assessed using the GRADE framework (Guyatt *et al.*, 2008). Disagreements were resolved by consensus with two additional reviewers (GL and SP).

Sensitivity analyses

In addition to those listed above sensitivity analyses were conducted if there was considerable heterogeneity (Higgins and

Green, 2011) either from inspection of the forest plots or if I^2 was 75% or above, or if either study quality was low or risk of bias was high, removing the study contributing most to the heterogeneity/low quality/high risk of bias.

Results

Characteristics of the included studies

In total nine RCTs met the inclusion criteria. IPD from all 4864 participants formed the present dataset, see Fig. 1.

Quality assessments and risk of bias

Overall, the risk of bias was low, and quality was high in all studies, so no sensitivity analyses were required in relation to these, although half of the studies had a moderate risk of bias related to attrition, see online Supplementary Tables 3 and 4. There was near perfect agreement between the reviewers, with interrater reliability (Cohen's Kappa) $k = 0.96$ for QUIPS and $k = 1.00$ for GRADE.

Descriptive statistics

Across all nine studies, age ranged between 16 and 84 years old at baseline with a mean age of approximately 42 years, 80% of the sample were aged between 23 and 61 years old. Approximately 67% of the participants were women, half of participants were married or cohabiting, approximately 30% were single and 20% no longer married (Table 3).

Association between age and prognosis independent of treatment

Overall, there was no evidence of an association between age and prognosis at 3–4 months post-baseline. This was the case when age was modelled as a continuous variable, an ordinal variable of age groups, comparing each age group to those aged 16–29 years old (see Table 4), and with age modelled with a quadratic term ($p = 0.233$). There was also no evidence of an association between age and prognosis at 6–8 months (online Supplementary Tables 7 and 8) or 9–12 months (online Supplementary Tables 9 and 10).

Associations between gender and prognosis independent of treatment

There was no evidence for a difference in prognosis between men and women at 3–4 months (Tables 4 and 5) or 9–12 months (online Supplementary Tables 9 and 10) post-baseline, but there was evidence that men had worse prognoses at 6–8 months (percentage difference in depressive symptoms for men compared to women: 15.08% (95% CI: 4.82 to 26.35), see online Supplementary Table 8). However, this was attenuated when adjusting for socio-demographic factors: age, marital status and employment, 12.23% (–1.69 to 28.12).

Associations between marital status and prognosis independent of treatment

There was some evidence of an association between marital status and prognosis at 3–4 months (Tables 4 and 5). Participants who were single (difference in mean depressive symptom score at 3–4 months (0.22(95% CI: 0.15 to 0.30)) and those who were no

longer married (0.28(95% CI: 0.20 to 0.37)), had more depressive symptoms at 3–4 months post-baseline on average, compared to married participants. After adjusting for the 'disorder characteristics' and socio-demographic factors there was still evidence that single or no longer married participants had worse prognoses than those that were married, but the strength of the associations was somewhat attenuated (see Tables 4 and 5). There were similar effects at 6–8 months post-baseline although confidence intervals included zero when controlling for employment status in addition to all other confounders with the log outcome (online Supplementary Tables 7 and 8). Further, when comparing just those participants who reported being single to those who reported being married, there was a lack of evidence for an association with prognosis at 6–8 months post-baseline after adjusting for depressive 'disorder characteristics'. At 9–12 months there was no evidence for an association between marital status and prognosis after adjusting for the depressive 'disorder characteristics' (online Supplementary Tables 9 and 10).

Sensitivity analyses

Sensitivity analyses including systematically missing confounding factors did not substantively change our conclusions (see online Supplementary tables 12–18), nor did analyses that removed studies due to high levels of heterogeneity (online Supplementary Table 19).

Discussion

This study investigated the associations between age, gender and marital status, with the prognosis of depression for adults that sought treatment in primary care, regardless of the type of treatment they were given. We found no evidence for an association between age and prognosis at 3–4, 6–8 or 9–12 months post-baseline and no evidence that gender was associated with prognosis after adjusting for clinical prognostic factors and employment status. There was evidence that single, and either separated, divorced or widowed patients (those no longer married) had worse prognoses than married patients at 3–4 months. However, the effect was weaker after adjusting for clinical prognostic factors and employment status.

Our recent review of systematic reviews and meta-analyses found inconsistent and at times contradictory findings regarding the associations between age, gender, marital status and prognosis for depressed patients (Buckman *et al.*, 2021). Our findings suggest that the pattern of associations found in those past reviews may have been due to chance, or the specific features of each review. With greater power to detect effects due to having a large IPD sample here, and additional robustness by adjusting for a range of treatments and for important clinical and demographic prognostic factors, we found no overall association between either age or gender and prognosis. Although we found that men appeared to have worse prognoses than women at 6–8 months this was attributable to a single large study that contributed data at the 6–8 months endpoint and not at 3–4 or 9–12 months, and the association was minimal after adjusting for clinical and demographic covariates. There had been limited evidence for an association between marital status and prognosis in prior reviews, here we did find evidence of such an association in our data (married patients did better with treatment). On the basis of our findings here it is unlikely that knowledge of patients' self-reported marital statuses will inform clinically meaningful differences in prognosis alone, particularly after accounting for depressive 'disorder characteristics'




Fig. 1. Flow of studies through selection process for IPD meta-analysis.

and employment status (Button *et al.*, 2015). However, it may be important to consider in conjunction with those other factors. The strength of the association with prognosis likely lies somewhere between the prognostic effects found for a history of antidepressant medication and comorbid panic disorder (Buckman *et al.*, 2021).

Strengths and limitations

To our knowledge, this is the first study to use a large individual patient dataset formed from a number of RCTs to consider the

prognostic status of age, gender, and marital status across different types of treatment, bringing greater precision to estimates of these associations than in past studies. In contrast to past reviews, we selected studies that included treatment seeking adults with depression recruited in primary care settings, as this is a very common route into treatment (McManus *et al.*, 2016; Thornicroft *et al.*, 2017). This may have limited the number of studies found to meet inclusion criteria for this review, but has the advantage of ensuring there is a minimum population for whom our findings may be generalisable. Further, as many of

Table 4. Difference in Z-score of depressive symptoms ('mean difference') at 3–4 months post-baseline per unit increase in baseline prognostic indicator

Baseline variable	Adjusted for treatment			Additionally adjusted for depressive severity and 'disorder characteristics'			Additionally adjusted for age, gender, and marital status			Additionally adjusted for age, gender, marital status, and employment status		
	Z-score of depressive symptoms	Number of Studies	Heterogeneity	Z-score of depressive symptoms	S Number of Studies	Heterogeneity	Z-score of depressive symptoms	Number of Studies	Heterogeneity	Z-score of depressive symptoms	Number of Studies	Heterogeneity
	Mean difference (95%CI)	K	I ²	Mean difference (95%CI)	K	I ²	Mean difference (95%CI)	K	I ²	Mean difference (95%CI)	K	I ²
Age (per 5 year increase)	-0.01(-0.04 to 0.01)	8	73	0(-0.02 to 0.02)	8	62	-0.06(-0.16 to 0.04)	8	0	-0.06(-0.16 to 0.04)	8	0
Age group	-0.03(-0.08 to 0.02)	8	74	0.01(-0.03 to 0.05)	8	65	-0.04(-0.13 to 0.05)	8	0	-0.05(-0.14 to 0.04)	8	0
Age (16–29 – reference)	0			0			0			0		
Age (30–39)	-0.07(-0.17 to 0.03)	8	0	-0.03(-0.13 to 0.07)	8	13	0.00(-0.11 to 0.11)	8	7	-0.01(-0.11 to 0.09)	8	0
Age (40–49)	-0.00(-0.21 to 0.21)	8	78	0.01(-0.13 to 0.16)	8	55	0.04(-0.10 to 0.19)	8	47	0.03(-0.12 to 0.18)	8	49
Age (50–59)	0.03(-0.15 to 0.16)	8	45	0.07(-0.08 to 0.21)	8	49	0.08(-0.06 to 0.23)	8	33	0.06(-0.08 to 0.19)	8	25
Age (60 +)	-0.14(-0.35 to 0.06)	8	63	0.05(-0.11 to 0.20)	8	39	0.06(-0.11 to 0.24)	8	40	0.05(-0.13 to 0.23)	8	46
Gender (women – reference)	0			0			0			0		
Gender (men)	0.01(-0.06 to 0.09)	8	7	0.05(-0.02 to 0.11)	8	0	0.05(-0.02 to 0.11)	8	0	0.03(-0.03 to 0.09)	8	0
Marital status	0.15(0.11 to 0.2)	8	0	0.1(0.06 to 0.14)	8	0	0.1(0.06 to 0.14)	8	0	0.08(0.04 to 0.12)	8	0
Married (reference)	0			0			0			0		
Single	0.22(0.15 to 0.30)	8	0	0.14(0.07 to 0.21)	8	2	0.15(0.08 to 0.23)	8	0	0.10(0.03 to 0.18)	8	0
No longer married	0.28(0.20 to 0.37)	8	0	0.18(0.10 to 0.26)	8	0	0.18(0.10 to 0.26)	8	0	0.13(0.05 to 0.21)	8	0

Note: Association for ordinal variables is per category increase from first category shown below the variable down to the last (i.e. married to single, single to no longer married). 'Disorder characteristics' adjusted for are: baseline BDI-II score, average anxiety duration, depression duration, comorbid panic disorder, and history of antidepressant treatment.

Table 5. Percentage difference ('% difference') in depressive symptom scale scores at 3–4 months post-baseline per unit increase in baseline prognostic indicator

Baseline variable	Adjusted for treatment			Additionally adjusted for depressive severity and 'disorder characteristics'			Additionally adjusted for age, gender, and marital status			Additionally adjusted for age, gender, marital status, and employment status		
	Percentage difference in depressive symptoms % difference (95%CI)	Number of studies <i>K</i>	Heterogeneity <i>I</i> ²	Percentage difference in depressive symptoms % difference (95%CI)	Number of studies <i>K</i>	Heterogeneity <i>I</i> ²	Percentage difference in depressive symptoms % difference (95%CI)	Number of studies <i>K</i>	Heterogeneity <i>I</i> ²	Percentage difference in depressive symptoms % difference (95%CI)	Number of Studies <i>K</i>	Heterogeneity <i>I</i> ²
Age (per 5 year increase)	-0.75(-2.61 to 1.14)	8	73	0.45(-1.27 to 2.20)	8	68	-2.10(-9.68 to 6.11)	8	0	-2.47(-9.97 to 5.66)	8	0
Age group	-1.45(-5.26 to 2.51)	8	73	0.97(-2.7 to 4.78)	8	69	-3.23(-10.19 to 4.27)	8	0	-4.03(-10.87 to 3.32)	8	0
Age (16–29 – reference)	0			0			0			0		
Age (30–39)	-8.41(-16.62 to 0.60)	8	19	-6.06(-14.13 to 2.78)	8	18	-3.45(-11.46 to 5.27)	8	6	-3.80(-11.60 to 4.70)	8	0
Age (40–49)	-3.08(-16.93 to 13.08)	8	73	-1.13(-10.69 to 9.46)	8	40	2.29(-7.49 to 13.11)	8	28	2.09(-7.82 to 13.06)	8	29
Age (50–59)	-0.58(-11.03 to 11.08)	8	40	3.57(-9.17 to 18.11)	8	57	6.24(-6.25 to 20.38)	8	43	4.50(-7.40 to 17.94)	8	38
Age (60 +)	-8.92(-24.30 to 9.59)	8	71	3.47(-11.23 to 20.62)	8	58	6.47(-9.63 to 25.43)	8	56	4.04(-12.67 to 23.94)	8	60
Gender (women – reference)	0			0			0			0		
Gender (men)	2.9(-2.53 to 8.63)	8	0	4.13(-1.1 to 9.63)	8	0	4.33(-1.03 to 9.99)	8	4	2.61(-3.02 to 8.56)	8	15
Marital status	10.07(6.61 to 13.64)	8	0	6.82(3.64 to 10.1)	8	0	6.81(3.61 to 10.12)	8	0	4.85(1.61 to 8.19)	8	3
Married (reference)	0			0			0			0		
Single	18.12(11.34 to 25.31)	8	0	12.02(5.95 to 18.44)	8	0	13.76(7.10 to 20.83)	8	0	9.25(2.78 to 16.13)	8	0
No longer married	19.17(11.64 to 27.21)	8	0	12.72(5.92 to 19.94)	8	0	11.97(5.10 to 19.29)	8	0	8.02(1.31 to 15.18)	8	0

Note: Association for ordinal variables is per category increase from first category shown below the variable down to the last (i.e. married to single, single to no longer married). 'Disorder characteristics' adjusted for are: baseline BDI-II score, average anxiety duration, depression duration, comorbid panic disorder and history of antidepressant treatment

the randomised treatments here are commonly used in other settings, our findings may be informative for clinicians assessing depressed patients in other settings where there are multiple treatment options.

In addition, our inclusion criteria specified such that all studies used the same measure to determine diagnosis, assess baseline symptoms and the depressive 'disorder characteristics' confounders, minimising bias in harmonising the data across studies. This reduced the potential pool of studies that might have been included here. However, as IPD data were available for all studies that met these criteria we did not introduce a common source of selection bias that can occur when only a subset of trials provide IPD. It is noteworthy that from our preliminary searches only two other studies (Hegerl *et al.*, 2010; Perroud *et al.*, 2012) (totalling $n = 612$ patients) might potentially have met all other inclusion criteria and used other comprehensive measures of depressive and anxiety symptoms and disorders at baseline. An alternative approach might have been taken by not specifying which measure was used at baseline but instead only specifying that all of the 'disorder characteristics' noted to be associated with prognosis in our previous study should have been assessed. It is noteworthy though that many studies that were excluded contained no comprehensive measure of anxiety disorder symptoms or diagnoses and so most would not have assessed for panic disorder, thus would have failed to meet inclusion criteria in this way too.

We used robust methods whereby data were extracted, cleaned and checked by multiple reviewers (Buscemi *et al.*, 2006), but only a one reviewer screened the initial titles and abstracts of the studies returned in the searches which may have introduced additional bias. Although adjustments were made for a number of potential confounders, including clinical, demographic and socio-economic variables, we cannot rule out residual confounding. Further, it is possible that adjusting for baseline depressive severity may have led to underestimating the effects of marital status on prognosis, as higher levels of baseline severity might be associated with a greater likelihood of separation, divorce or of being single. In addition, using a standardised outcome is a method that has been criticised but the results using the z -score outcome were similar to those with the log outcome and the secondary and sensitivity outcomes, suggesting the use of the standardised outcome metric did not unduly affect the results. The included studies were conducted at such a time when only two categories of gender were routinely assessed and did not give participants the option to identify with non-binary gender identities. Two participants had no gender data recorded; it is not clear whether they would have chosen another gender identity were other categories available to them.

Implications and conclusions

Clinicians and researchers will continue to routinely assess for age and gender however the value of including information on these factors when considering prognosis is likely to be very limited. On the basis of these findings we might conclude that although age and gender are important for the incidence and prevalence of depression (Kessler *et al.*, 2005), they appear to not be important for prognosis with treatment. Patients that are married appear to have better prognoses than patients that are single or no longer married. On its own, marital status is unlikely to inform a clinically important difference in prognosis after accounting for the severity of depressive illness, captured by the depressive 'disorder characteristics'. However, as the magnitude of effects was similar to those of a number of other clinical prognostic factors, it may be

equally important to assess for marital status in clinic and to include it in predictive models of prognosis. We were unable to investigate why married people have better prognoses. It is noteworthy that when adjusting for housing status, financial wellbeing and social support (in sensitivity analyses) the associations were weaker, so married patients might differ from those that are not married in these social domain, and these in turn may be associated with prognosis.

Supplementary material. The supplementary material for this article can be found at <https://doi.org/10.1017/S2045796021000342>

Data availability. Requests for sharing of the IPD used in this study can be made to the corresponding author, any sharing of data will be subject to obtaining appropriate agreements from the chief investigators or data custodians for each individual trial dataset used here.

Acknowledgements. The authors would like to thank Professor Ian R. White for his contribution to determining the methods for this study and writing the protocol paper that this study followed.

Authors contributions. JB, GL and SP conceived of the original project, all three along with SDH, RJD, SG, TK, EW and GA applied for and received funding to support this work. All nine of the above, RS and ZDC, wrote the initial protocol document and plan for the current study. JB and RS co-reviewed the studies with consultation from GL and SP. ZDC, NW, DK, GA and GL provided data and liaison to resolve issues and discrepancies between received datasets and publications about those studies. JB, RS, GL and SP were responsible for the screening of studies, data extraction, additional data cleaning. JB was responsible for the data analysis with support from GA, GL, CO'D, L-LA, JS and RS in particular, and consultation from all other authors. JB wrote the original manuscript with support from RS, L-LA, JS, CO'D, GA, TE, MD, SDH, SB, EL, ZDC, GL and SP. All authors contributed to consecutive drafts and approved the final manuscript. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting criteria have been omitted.

Financial support. This work was supported by the Wellcome Trust through a Clinical Research Fellowship to JB (201292/Z/16/Z), MQ Foundation (for ZC: MQDS16/72), the Higher Education Funding Council for England (RS, L-LA, CO'D and SP), the National Institute of Health Research (NIHR), NIHR University College London Hospitals Biomedical Research Centre (RS, L-LA and SP), University College London (GA, GL), Vanderbilt University (SDH), University of Southampton (TK), University of Exeter (EW) and University of York (SG). NIHR Biomedical Research Centre at the University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol (NW: The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care). Alzheimer's Society (grant code: 457 (AS-PG-18-013) for JS). National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London (TE and MD: The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health).

The studies that IPD for this study were funded by:

1. CADET: UK Medical Research Council (MRC; reference G0701013), managed by the National Institute for Health Research (NIHR) on behalf of the MRC-NIHR partnership
2. COBALT: This research was funded by the National Institute for Health Research Health Technology Assessment (NIHR HTA) programme (project number 06/404/02).
3. GENPOD: Medical Research Council and supported by the Mental Health Research Network.
4. IPCRESS: BUPA Foundation
5. ITAS: Primary Secondary Care Interface initiative of the United Kingdom National Health Service Research and Development Programme (PSI 2-58).

6. MIR: National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project 11/129/76) and supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol
7. PANDA: NIHR Programme Grant for Applied Research (RP-PG-0610-10048).
8. REEACT: UK National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (project 06/43/05).
9. TREAD: National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme.

The funding sources had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.

Conflict of interest. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. Declaration of Interest: None.

References

- Bebbington P** (1987) Marital status and depression: a study of English national admission statistics. *Acta Psychiatrica Scandinavica* **75**, 640–650.
- Beck AT, Steer RA and Brown GK** (1996) Manual for the Beck depression inventory-II. *Manual for the Beck Depression Inventory-II*. San Antonio, TX: Psychological Corporation, pp. 1–82.
- Buckman JEJ, Saunders R, Cohen ZD, Clarke K, Ambler G, DeRubeis RJ, Gilbody S, Hollon SD, Kendrick T, Watkins E, White IR, Lewis G and Pilling S** (2020) What factors indicate prognosis for adults with depression in primary care? A protocol for meta-analyses of individual patient data using the Dep-GP database. *Wellcome Open Research* **4**. Available at <https://www.cambridge.org/core/journals/psychological-medicine/article/contribution-of-depressive-disorder-characteristics-to-determinations-of-prognosis-for-adults-with-depression-an-individual-patient-data-metaanalysis/65C312B2870A61B90FBB8A0CCD1A145E> (Accessed 4 May 2021).
- Buckman JEJ, Saunders R, Cohen ZD, Barnett P, Clarke K, Ambler G, DeRubeis RJ, Gilbody S, Hollon SD, Kendrick T, Watkins E, Wiles N, Kessler D, Richards D, Sharp D, Brabyn S, Littlewood E, Salisbury C, White IR, Lewis G and Pilling S** (2021) The contribution of depressive “disorder characteristics” to determinations of prognosis for adults with depression: an individual patient data metaanalysis. *Psychological Medicine* [Published Online]. Available at <https://wellcomeopenresearch.org/articles/4-69> (Accessed 4 May 2021).
- Buscemi N, Hartling L, Vandermeer B, Tjosvold L and Klassen TP** (2006) Single data extraction generated more errors than double data extraction in systematic reviews. *Journal of Clinical Epidemiology* **59**, 697–703.
- Button KS, Kounali D, Thomas L, Wiles NJ, Peters TJ, Welton NJ, Ades AE and Lewis G** (2015) Minimal clinically important difference on the Beck depression inventory – II according to the patient’s perspective. *Psychological Medicine* **45**, 3269–3279.
- Carter GC, Cantrell RA, Zarotsky V, Haynes VS, Phillips G, Alatorre CI, Goetz I, Paczkowski R and Marangell LB** (2012) Comprehensive review of factors implicated in the heterogeneity of response in depression. *Depression and Anxiety* **29**, 340–354.
- Chalder N, Wiles NJ, Campbell J, Hollinghurst SP, Haase AM, Taylor AH, Fox KR, Costelloe C, Searle A, Baxter H, Winder R, Wright C, Turner KM, Calnan M, Lawlor DA, Peters TJ, Sharp DJ, Montgomery AA and Lewis G** (2012) Facilitated physical activity as a treatment for depressed adults: randomised controlled trial. *British Medical Journal* **344**, e2758–e2758.
- Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH and Corlett PR** (2016) Cross-trial prediction of treatment outcome in depression: a machine learning approach. *The Lancet Psychiatry* **3**, 243–250.
- Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA and Geddes JR** (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet* **391**, 1357–1366.
- Cox BD, Blaxter M, Buckle ALJ, Fenner NP, Golding JF, Gore M, Huppert FA, Nickson J, Roth M, Stark J, Wadsworth MEJ and Wichelow M** (1987) *The Health and Lifestyle Survey*. London, UK: Health Promotion Research Trust.
- Cuijpers P, Hollon SD, van Straten A, Bockting C, Berking M and Andersson G** (2013) Does cognitive behaviour therapy have an enduring effect that is superior to keeping patients on continuation pharmacotherapy? A meta-analysis. *BMJ Open* **3**, e002542.
- Cuijpers P, Karyotaki E, Reijnders M and Huibers MJH** (2018) Who benefits from psychotherapies for adult depression? A meta-analytic update of the evidence. *Cognitive Behaviour Therapy* **47**, 91–106.
- Dodd S, Berk M, Kelin K, Zhang Q, Eriksson E, Deberdt W and Craig Nelson J** (2014) Application of the gradient boosted method in randomised clinical trials: participant variables that contribute to depression treatment efficacy of duloxetine, SSRIs or placebo. *Journal of Affective Disorders* **168**, 284–293.
- Ensel WM** (1982) The role of age in the relationship of gender and marital status to depression. *The Journal of Nervous and Mental Disease* **170**, 536–543.
- Faravelli C, Alessandra Scarpato M, Castellini G and Lo Sauro C** (2013) Gender differences in depression and anxiety: the role of age. *Psychiatry Research* **210**, 1301–1303.
- Fisher DJ** (2015) Two-stage individual participant data meta-analysis and generalized forest plots. *The Stata Journal* **2**, 369–396.
- Gilbody S, Littlewood E, Hewitt C, Brierley G, Tharmanathan P, Araya R, Barkham M, Bower P, Cooper C, Gask L, Kessler D, Lester H, Lovell K, Parry G, Richards DA, Andersen P, Brabyn S, Knowles S, Shepherd C, Tallon D and White D** (2015) Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic randomised controlled trial. *British Medical Journal* **351**, h5627.
- Goldberg D** (1992) *General Health Questionnaire (GHQ-12) NFER*. Windsor, UK: Nelson Publishing Co. Ltd.
- Guyatt GH, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P and Schünemann HJ** (2008) GRADE An emerging consensus on rating quality of evidence and strength of recommendations. *British Medical Journal* **336**, 924–926.
- Hayden JA, Van Der Windt DA, Cartwright JL, Côté P and Bombardier C** (2013) Assessing bias in studies of prognostic factors. *Annals of Internal Medicine* **158**, 280–286.
- Hegerl U, Hautzinger M, Mergl R, Kohlen R, Schütze M, Scheunemann W, Allgaier A-K, Coyne J and Henkel V** (2010) Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients’ choice arm. *The International Journal of Neuropsychopharmacology* **13**, 31–44.
- Higgins JPT and Green S** (2011) *Cochrane Handbook for Systematic Reviews of Interventions*. Edited by J. P. T. Higgins and S. Geen. Chichester, UK: The Cochrane Collaboration.
- Higgins JPT, Thompson SG, Deeks JJ and Altman DG** (2003) Measuring inconsistency in meta-analyses. *British Medical Journal* **327**, 557–560.
- Johnsen TJ and Friborg O** (2015) The effects of cognitive behavioral therapy as an anti-depressive treatment is falling: a meta-analysis. *Psychological Bulletin* **141**, 747–768.
- Karyotaki E, Riper H, Twisk J, Hoogendoorn A, Kleiboer A, Mira A, Mackinnon A, Meyer B, Botella C, Littlewood E, Andersson G, Christensen H, Klein JP, Schröder J, Bretón-López J, Scheider J, Griffiths K, Farrer L, Huibers MJH, Phillips R, Gilbody S, Moritz S, Berger T, Pop V, Spek V and Cuijpers P** (2017) Efficacy of self-guided internet-based cognitive behavioral therapy in the treatment of depressive symptoms. *JAMA Psychiatry* **74**, 351–359.
- Kessler RC and Essex M** (1982) Marital status and depression: the importance of coping resources. *Social Forces* **61**, 484–507.
- Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR and Walters EE** (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. *Archives of General Psychiatry* **62**, 593–602.
- Kessler D, Lewis G, Kaur S, Wiles N, King M, Weich S, Sharp DJ, Araya R, Hollinghurst S and Peters TJ** (2009) Therapist-delivered internet psychotherapy for depression in primary care: a randomised controlled trial. *The Lancet* **374**, 628–634.

- Kessler DS, MacNeill SJ, Tallon D, Lewis G, Peters TJ, Hollingworth W, Round J, Burns A, Chew-Graham CA, Anderson IM, Shepherd T, Campbell J, Dickens CM, Carter M, Jenkinson C, Macleod U, Gibson H, Davies S and Wiles NJ (2018) Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). *British Medical Journal* **363**, k4218.
- Kroenke K, Spitzer RL and Williams JBW (2001) The PHQ-9. *Journal of General Internal Medicine* **16**, 606–613.
- Lewis G, Pelosi AJ, Araya R and Dunn G (1992) Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers. *Psychological Medicine* **22**, 465–486.
- Lewis G, Duffy L, Ades A, Amos R, Araya R, Brabyn S, Button KS, Churchill R, Derrick C, Dowrick C, Gilbody S, Fawsitt C, Hollingworth W, Jones V, Kendrick T, Kessler D, Kounali D, Khan N, Lanham P, Pervin J, Peters TJ, Riozzie D, Salaminios G, Thomas L, Welton NJ, Wiles N, Woodhouse R and Lewis, G (2019) The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial. *The Lancet Psychiatry* **6**, 903–914.
- McManus S, Bebbington P, Jenkins R and Brugha TS (2016) *Mental Health and Wellbeing in England: Adult Psychiatric Morbidity Survey 2014*. Leeds, UK: NHS Digital.
- Menchetti M, Bortolotti B, Rucci P, Scocco P, Bombi A and Berardi D (2010) Depression in primary care: interpersonal counseling vs selective serotonin reuptake inhibitors. The DEPICS study. A multicenter randomized controlled trial. Rationale and design. *BMC Psychiatry* **10**, 1–9. Available at <https://bmcp psychiatry.biomedcentral.com/articles/10.1186/1471-244X-10-97> (Accessed 4 May 2021).
- Nakabayashi T, Hara A and Minami H (2018) Impact of demographic factors on the antidepressant effect: a patient-level data analysis from depression trials submitted to the pharmaceuticals and medical devices agency in Japan. *Journal of Psychiatric Research* **98**, 116–123.
- Noma H, Furukawa TA, Maruo K, Imai H, Shinohara K, Tanaka S, Ikeda K, Yamawaki S and Cipriani A (2019) Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. *Journal of Affective Disorders* **250**, 419–424.
- Olfson M, Blanco C and Marcus SC (2016) Treatment of adult depression in the United States. *JAMA Internal Medicine* **176**, 1482–1491.
- Perroud N, Uher R, Ng MYM, Guipponi M, Hauser J, Henigsberg N, Maier W, Mors O, Gennarelli M, Rietschel M, Souery D, Dernovsek MZ, Stamp AS, Lathrop M, Farmer A, Breen G, Aitchison KJ, Lewis CM, Craig IW and McGuffin P (2012) Genome-wide association study of increasing suicidal ideation during antidepressant treatment in the GENDEP project. *The Pharmacogenomics Journal* **12**, 68–77.
- Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D, Page MJ and Koffel JB (2021) PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews. *Systematic Reviews* **10**, 1–19. Available at <https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-020-01542-z> (Accessed 4 May 2021).
- Richards DA, Hill JJ, Gask L, Lovell K, Chew-Graham C, Bower P, Cape J, Pilling S, Araya R, Kessler D, Bland JM, Green C, Gilbody S, Lewis G, Manning C, Hughes-Morley A and Barkham M (2013) Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trial. *British Medical Journal* **347**, f4913–f4913.
- Rothwell PM (2005) Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. *The Lancet* **365**, 176–186.
- Schoemaker JH, Kilian S, Emsley R and Vingerhoets AJJM (2018) Factors associated with placebo response in depression trials: a systematic review of published meta-analyses (1990–2017). *Neurology Psychiatry and Brain Research* **30**, 12–21.
- Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA and the PRISMA-P Group (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *British Medical Journal* **349**, 1–25.
- Socket LE (2018) A systematic review and meta-analysis of interpersonal psychotherapy for perinatal women. *Journal of Affective Disorders* **232**, 316–328.
- StataCorp (2019) *Stata Statistical Software: Release 16*. Stata Statistical Software. College Station, TX: StataCorp LLC.
- Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G and Tierney JF (2015) Preferred reporting items for a systematic review and meta-analysis of individual participant data. *Journal of the American Medical Association* **313**, 1657–1665.
- Thomas HV, Lewis G, Watson M, Thomas HV, Lewis G, Watson, M, Bell T, Lyons I, Lloyd K, Weich S and Sharp D (2004) Computerised patient-specific guidelines for management of common mental disorders in primary care: a randomised controlled trial. *British Journal of General Practice* **54**, 832–837.
- Thornicroft G, Chatterji S, Evans-Lacko S, Gruber M, Sampson N, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Andrade L, Borges G, Bruffaerts R, Bunting B, De Almeida JMC, Florescu S, De Girolamo G, Gureje O, Haro JM, He Y, Hinkov H, Karam E, Kawakami N, Lee S, Navarro-Mateu F, Piazza M, Posada-Villa J, De Galvis YT and Kessler RC (2017) Undertreatment of people with major depressive disorder in 21 countries. *British Journal of Psychiatry* **210**, 119–124.
- Trusheim MR, Berndt ER and Douglas FL (2007) Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. *Nature Reviews Neuroscience* **6**, 287–293.
- Weitz E, Kleiboer A, Van Straten A, Hollon SD and Cuijpers P (2017) Individual patient data meta-analysis of combined treatments versus psychotherapy (with or without pill placebo), pharmacotherapy or pill placebo for adult depression: a protocol. *BMJ Open* **7**, 1–8.
- Wiles NJ, Mulligan J, Peters TJ, Cowen PJ, Mason V, Nutt D, Sharp D, Tallon D, Thomas L, O'Donovan MC and Lewis G (2012) Severity of depression and response to antidepressants: GENPOD randomised controlled trial. *British Journal of Psychiatry* **200**, 130–136.
- Wiles N, Thomas L, Abel A, Ridgway N, Turner N, Campbell J, Garland A, Hollinghurst S, Jerrom B, Kessler D, Kuyken W, Morrison J, Turner K, Williams C, Peters T and Lewis G (2013) Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBaIT randomised controlled trial. *The Lancet* **381**, 375–384.